A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
Interventions: DRUG: SHR-A1811|DRUG: Pyrotinib in combination with Capecitabine.
Sponsor: Jiangsu HengRui Medicine Co., Ltd.